David González

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González et al. · The Lancet Oncology · 2013 · 723 citations · Full text

Oncology, Open-label Phase 3, Cancer Management +7

Mismatch Repair Deficiency, Microsatellite Instability, and Survival

Elizabeth Smyth, Andrew Wotherspoon, Clare Peckitt et al. · JAMA Oncology · 2017 · 509 citations · Full text

Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936

Paul Evans, Ch Pott, Patricia J.T.A. Groenen et al. · Leukemia · 2006 · 296 citations

B-cell Malignancies, Lymphoid Neoplasia, Hematological Malignancy +7

Mutational Status of the <i>TP53</i> Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

David González, Pilar Martı́nez, Rachel Wade et al. · Journal of Clinical Oncology · 2011 · 263 citations

Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis

Andrew G. Nicholson, David González, Pallav L. Shah et al. · Journal of Thoracic Oncology · 2010 · 213 citations · Full text

Egfr Mutation Analysis, Medicine, Multiple Pulmonary Nodule +9